Insider · CIK 0001278386
Broadwood Partners, L.p.
Files at STAA (STAAR SURGICAL CO), LCTX (Lineage Cell Therapeutics, Inc.), IMDX (Insight Molecular Diagnostics Inc.). First filing Dec 18, 2024, latest Apr 27, 2026.
Broadwood Partners, L.p. files SEC Form 4 as 10% owner and director at STAA (STAAR SURGICAL CO), and also at IMDX (Insight Molecular Diagnostics Inc.), LCTX (Lineage Cell Therapeutics, Inc.). Since Dec 18, 2024, Broadwood Partners, L.p. has reported 20 open-market buys worth $131M and 0 open-market sells worth $0, the latest filed on Apr 27, 2026.
A track record needs three past buys with six months of prices behind them; Broadwood Partners, L.p. has 0, so none is measured yet.
The newest scored trade: bought $2.0M of IMDX on Apr 23, 2026, filed Apr 27, 2026, scored 45 (moderate). In the last 12 months: 7 buys worth $68M and 0 sells worth $0.
Where the trades landed
Last year at the 3 companies this insider has traded most, with each buy and sell on the bar it happened.
STAA: STAAR SURGICAL CO
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
IMDX: Insight Molecular Diagnostics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
LCTX: Lineage Cell Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | IMDXbuy Insight Molecular Diagnostics Inc. | $2.0M 570,184 shares | +5% | +47% from low-58% from high | |
| 40Moderate | IMDXbuy Insight Molecular Diagnostics Inc. | $653k 182,861 shares | +2% | +46% from low-59% from high | |
| 53Moderate | STAAbuy STAAR SURGICAL CO | $12M 670,213 shares | +4% | +17% from low-38% from high | |
| 32Weak | IMDXbuy Insight Molecular Diagnostics Inc. | $3.0M 521,739 shares | +5% | +258% from low-13% from high | |
| 30Weak | STAAbuy STAAR SURGICAL CO | $606k 27,485 shares | +0% | +47% from low-23% from high | |
| 41Moderate | STAAbuy STAAR SURGICAL CO | $8.8M 406,653 shares | +3% | +48% from low-22% from high | |
| 35Weak | STAAbuy STAAR SURGICAL CO | $41M 1,500,000 shares | +11% | +75% from low-9% from high | |
| 55Moderate | STAAbuy STAAR SURGICAL CO | $2.9M 187,227 shares | +1% | 0% from low-59% from high | |
| 48Moderate | STAAbuy STAAR SURGICAL CO | $14M 845,220 shares | +7% | +13% from low-53% from high | |
| 39Weak | STAAbuy STAAR SURGICAL CO | $941k 53,969 shares | +0% | +15% from low-53% from high | |
| 40Moderate | STAAbuy STAAR SURGICAL CO | $2.0M 113,384 shares | +1% | +14% from low-53% from high | |
| 45Moderate | STAAbuy STAAR SURGICAL CO | $2.4M 136,696 shares | +1% | +15% from low-52% from high | |
| 45Moderate | STAAbuy STAAR SURGICAL CO | $3.6M 201,844 shares | +2% | +19% from low-51% from high | |
| 25Weak | STAAbuy STAAR SURGICAL CO | $482k 27,953 shares | +0% | - | |
| 40Moderate | STAAbuy STAAR SURGICAL CO | $11M 663,761 shares | +6% | - | |
| 37Weak | STAAbuy STAAR SURGICAL CO | $6.3M 411,430 shares | +4% | - | |
| 50Moderate | Insight Molecular Diagnostics Inc. | $11M 5,165,695 shares | +83% | - | |
| 43Moderate | LCTXbuy Lineage Cell Therapeutics, Inc. | $6.0M 7,894,737 shares | +19% | - | |
| 27Weak | STAAbuy STAAR SURGICAL CO | $631k 29,376 shares | +0% | - | |
| 27Weak | STAAbuy STAAR SURGICAL CO | $1.9M 80,200 shares | +1% | - |
Transactions
The newest 50 of 120 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +280,381 | $3.50 | $982k | 12,395,081 | Apr 27, 2026 |
| Apr 23, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,395,081 | Apr 27, 2026 |
| Apr 24, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +38,880 | $3.53 | $137k | 12,433,961 | Apr 27, 2026 |
| Apr 24, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,433,961 | Apr 27, 2026 |
| Apr 27, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +250,923 | $3.64 | $913k | 12,684,884 | Apr 27, 2026 |
| Apr 27, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,684,884 | Apr 27, 2026 |
| Apr 16, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +102,057 | $3.45 | $352k | 12,033,896 | Apr 20, 2026 |
| Apr 16, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,033,896 | Apr 20, 2026 |
| Apr 17, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +40,114 | $3.57 | $143k | 12,074,010 | Apr 20, 2026 |
| Apr 17, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,074,010 | Apr 20, 2026 |
| Apr 20, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +40,690 | $3.88 | $158k | 12,114,700 | Apr 20, 2026 |
| Apr 20, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 12,114,700 | Apr 20, 2026 |
| Mar 11, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +54,764 | $17.52 | $960k | 15,508,393 | Mar 13, 2026 |
| Mar 11, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,508,393 | Mar 13, 2026 |
| Mar 12, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +299,432 | $18.12 | $5.4M | 15,807,825 | Mar 13, 2026 |
| Mar 12, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,807,825 | Mar 13, 2026 |
| Mar 13, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +316,017 | $18.62 | $5.9M | 16,123,842 | Mar 13, 2026 |
| Mar 13, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 16,123,842 | Mar 13, 2026 |
| Feb 10, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par value | +521,739 | $5.75 | $3.0M | 11,931,839 | Feb 12, 2026 |
| Feb 10, 2026 | IMDX Insight Molecular Diagnostics Inc. | POpen-market purchase Common Stock, no par valueindirect: Footnote | +0 | $0.00 | $0 | 11,931,839 | Feb 12, 2026 |
| Jan 9, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +27,485 | $22.05 | $606k | 15,453,629 | Jan 13, 2026 |
| Jan 9, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,453,629 | Jan 13, 2026 |
| Jan 6, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +186,946 | $21.01 | $3.9M | 15,206,437 | Jan 8, 2026 |
| Jan 6, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,206,437 | Jan 8, 2026 |
| Jan 6, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +150,000 | $22.38 | $3.4M | 15,356,437 | Jan 8, 2026 |
| Jan 6, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,356,437 | Jan 8, 2026 |
| Jan 7, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +66,467 | $22.00 | $1.5M | 15,422,904 | Jan 8, 2026 |
| Jan 7, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,422,904 | Jan 8, 2026 |
| Jan 8, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +3,240 | $21.94 | $71k | 15,426,144 | Jan 8, 2026 |
| Jan 8, 2026 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,426,144 | Jan 8, 2026 |
| Nov 19, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +309,132 | $26.42 | $8.2M | 13,828,623 | Nov 21, 2025 |
| Nov 19, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,828,623 | Nov 21, 2025 |
| Nov 20, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +393,382 | $27.14 | $11M | 14,222,005 | Nov 21, 2025 |
| Nov 20, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 14,222,005 | Nov 21, 2025 |
| Nov 21, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +797,486 | $27.86 | $22M | 15,019,491 | Nov 21, 2025 |
| Nov 21, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 15,019,491 | Nov 21, 2025 |
| Apr 8, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +166,527 | $15.28 | $2.5M | 13,498,791 | Apr 10, 2025 |
| Apr 8, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,498,791 | Apr 10, 2025 |
| Apr 8, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +11,600 | $15.95 | $185k | 13,510,391 | Apr 10, 2025 |
| Apr 8, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,510,391 | Apr 10, 2025 |
| Apr 9, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +8,200 | $15.08 | $124k | 13,518,591 | Apr 10, 2025 |
| Apr 9, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,518,591 | Apr 10, 2025 |
| Apr 10, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +900 | $15.18 | $14k | 13,519,491 | Apr 10, 2025 |
| Apr 10, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,519,491 | Apr 10, 2025 |
| Apr 3, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +209,535 | $16.97 | $3.6M | 12,696,579 | Apr 7, 2025 |
| Apr 3, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 12,696,579 | Apr 7, 2025 |
| Apr 4, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +492,631 | $15.90 | $7.8M | 13,189,210 | Apr 7, 2025 |
| Apr 4, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,189,210 | Apr 7, 2025 |
| Apr 4, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stock | +5,000 | $16.46 | $82k | 13,194,210 | Apr 7, 2025 |
| Apr 4, 2025 | STAA STAAR SURGICAL CO | POpen-market purchase Common Stockindirect: Footnote | +0 | $0.00 | $0 | 13,194,210 | Apr 7, 2025 |
Questions about Broadwood Partners, L.p.
Answered from the filings on this page, as of the latest one.
Is Broadwood Partners, L.p. buying or selling?
In the last 12 months Broadwood Partners, L.p. reported 7 open-market buys worth $68M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.0M of IMDX on Apr 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Broadwood Partners, L.p.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Broadwood Partners, L.p. has 0.
Where does Broadwood Partners, L.p. file Form 4?
Broadwood Partners, L.p. has filed Form 4 at STAA (STAAR SURGICAL CO); IMDX (Insight Molecular Diagnostics Inc.); LCTX (Lineage Cell Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.